BioStock-article: FOLLICUM IS CLOSING IN ON PROOF-OF-CONCEPT FOR HAIR LOSS PRODUCT
BioStock published an article on 30 September 2019 about Follicum, which can be read in full below. Follicum’s business strategy is to enter into a partnership, out license or sell their candidates following phase II trials at the latest. With proof-of-concept and top-line-data for FOL-005 firmly within reach during 2020, the company is getting closer and closer to realising its business model.Follicum develops pharmaceutical drugs with First-in-Class potential, i.e., completely new treatment concepts with unique mechanisms of action within the field of stimulation